Eisai’s lecanemab-irmb was converted from an accelerated approval to a traditional approval.
FDA announced on July 6, 2023, that it had converted its approval of Eisai’s Leqembi (lecanemab-irmb), indicated to treat patients with Alzheimer's Disease, from an accelerated approval to a traditional approval. Originally granted approval in January, the conversion followed a confirmatory trial which FDA determined verified clinical benefit. Lecanemab-irmb is an amyloid beta-directed therapy that is designed to reduce amyloid plaques that form in the brain, which is a defining pathophysiological feature of Alzheimer’s Disease.
The confirmatory study, Study 301, was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study that enrolled 1,795 Alzheimer’s patients with mild cognitive impairment or mild dementia stage of disease and confirmed presence of amyloid beta pathology. According to the release, lecanemab-irmb demonstrated a statistically significant and clinically meaningful reduction of decline from baseline to 18 months on the primary endpoint, the Clinical Dementia Rating Scale Sum of Boxes score, relative to placebo. Statistically significant differences between treatment groups were also demonstrated on all secondary endpoints.
“Today’s action is the first verification that a drug targeting the underlying disease process of Alzheimer’s disease has shown clinical benefit in this devastating disease,” said Teresa Buracchio, acting director, Office of Neuroscience, Center for Drug Evaluation and Research, FDA, in the release. “This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer’s disease.”
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.